185 related articles for article (PubMed ID: 22674696)
1. Successful use of nitazoxanide in the treatment of recurrent Clostridium difficile infection.
Rafiullah F; Kanwal S; Majeed UM; Korsten MA; Cheema FH; Luthra M; Sohail MR
BMJ Case Rep; 2011 Nov; 2011():. PubMed ID: 22674696
[TBL] [Abstract][Full Text] [Related]
2. Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice.
Warren CA; van Opstal EJ; Riggins MS; Li Y; Moore JH; Kolling GL; Guerrant RL; Hoffman PS
Antimicrob Agents Chemother; 2013 Feb; 57(2):689-96. PubMed ID: 23147742
[TBL] [Abstract][Full Text] [Related]
3. Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide.
Musher DM; Logan N; Mehendiratta V; Melgarejo NA; Garud S; Hamill RJ
J Antimicrob Chemother; 2007 Apr; 59(4):705-10. PubMed ID: 17337513
[TBL] [Abstract][Full Text] [Related]
4. Continuing diarrhoea after ten days of oral metronidazole or oral vancomycin for presumed, hospital-acquired Clostridium difficile colitis in elderly hospital patients.
Parks T; Wallis S; Wilson J; Gkrania-Klotsas E; Nicholl C
J Hosp Infect; 2010 Apr; 74(4):403-5. PubMed ID: 20153080
[No Abstract] [Full Text] [Related]
5. Does Addition of Intravenous Metronidazole to Oral Vancomycin Improve Outcomes in Clostridioides difficile Infection?
Wang Y; Schluger A; Li J; Gomez-Simmonds A; Salmasian H; Freedberg DE
Clin Infect Dis; 2020 Dec; 71(9):2414-2420. PubMed ID: 31714955
[TBL] [Abstract][Full Text] [Related]
6. Current state of Clostridium difficile treatment options.
Venugopal AA; Johnson S
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S71-6. PubMed ID: 22752868
[TBL] [Abstract][Full Text] [Related]
7. Use of Oral Vancomycin for Clostridioides difficile Infection and the Risk of Vancomycin-Resistant Enterococci.
Stevens VW; Khader K; Echevarria K; Nelson RE; Zhang Y; Jones M; Timbrook TT; Samore MH; Rubin MA
Clin Infect Dis; 2020 Jul; 71(3):645-651. PubMed ID: 31504328
[TBL] [Abstract][Full Text] [Related]
8. Characterization and risk factors for recurrence of Clostridioides (Clostridium) difficile infection in Japan: A nationwide real-world analysis using a large hospital-based administrative dataset.
Kimura T; Snijder R; Sugitani T
J Infect Chemother; 2019 Aug; 25(8):615-620. PubMed ID: 30987950
[TBL] [Abstract][Full Text] [Related]
9. Best strategies in recurrent or persistent Clostridium difficile infection.
Cocanour CS
Surg Infect (Larchmt); 2011 Jun; 12(3):235-9. PubMed ID: 21767157
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo activities of nitazoxanide against Clostridium difficile.
McVay CS; Rolfe RD
Antimicrob Agents Chemother; 2000 Sep; 44(9):2254-8. PubMed ID: 10952564
[TBL] [Abstract][Full Text] [Related]
11. Outcomes associated with recent guideline recommendations removing metronidazole for treatment of non-severe Clostridioides difficile infection: a retrospective, observational, nationwide cohort study.
Gentry CA; Campbell DL; Williams RJ
Int J Antimicrob Agents; 2021 Mar; 57(3):106282. PubMed ID: 33465458
[TBL] [Abstract][Full Text] [Related]
12. Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study.
Musher DM; Logan N; Bressler AM; Johnson DP; Rossignol JF
Clin Infect Dis; 2009 Feb; 48(4):e41-6. PubMed ID: 19133801
[TBL] [Abstract][Full Text] [Related]
13. Severe anaphylaxis caused by orally administered vancomycin to a patient with Clostridium difficile infection.
Bossé D; Lemire C; Ruel J; Cantin AM; Ménard F; Valiquette L
Infection; 2013 Apr; 41(2):579-82. PubMed ID: 22996384
[TBL] [Abstract][Full Text] [Related]
14. Clostridium difficile treatment in neutropenic patients: Clinical outcomes of metronidazole, vancomycin, combinations, and switch therapy.
Tieu JD; Schmidt SA; Miller JL; Kupiec KE; Skrepnek GH; Liu C; Smith WJ
J Oncol Pharm Pract; 2019 Apr; 25(3):520-528. PubMed ID: 29157145
[TBL] [Abstract][Full Text] [Related]
15. Changes in treatment of community-onset Clostridioides difficile infection after release of updated guidelines, Atlanta, Georgia, 2018.
Adelman MW; Goodenough D; Sefton S; Mackey C; Thomas S; Fridkin SK; Woodworth MH
Anaerobe; 2021 Aug; 70():102364. PubMed ID: 33862203
[TBL] [Abstract][Full Text] [Related]
16. Non-inferiority of metronidazole to vancomycin in the treatment of first episode non-severe Clostridioides difficile infection: a single center retrospective cohort study.
Najjar-Debbiny R; Bazazhina A; Schwartz N; Shaked P; Saliba W; Weber G
Infection; 2022 Aug; 50(4):973-980. PubMed ID: 35192148
[TBL] [Abstract][Full Text] [Related]
17. Recurrent bacteremia and liver abscess caused by Clostridium difficile: A case report.
Morioka H; Iguchi M; Kuzuya T; Mikamo H; Yagi T
Medicine (Baltimore); 2017 Sep; 96(35):e7969. PubMed ID: 28858131
[TBL] [Abstract][Full Text] [Related]
18. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials.
Johnson S; Louie TJ; Gerding DN; Cornely OA; Chasan-Taber S; Fitts D; Gelone SP; Broom C; Davidson DM;
Clin Infect Dis; 2014 Aug; 59(3):345-54. PubMed ID: 24799326
[TBL] [Abstract][Full Text] [Related]
19. Fecal Microbiota Transplantation in Recurrent NAP1/B1/027 Clostridium Difficile Infection (CDI) Resistant to Vancomycin and Metronidazole in a Patient with Ulcerative Colitis (UC): A Case Report.
Preda CM; Meianu C; Sandra I; Becheanu G; Dumbrava M; Manuc M; Diculescu M
Rev Med Chir Soc Med Nat Iasi; 2016; 120(3):563-7. PubMed ID: 30044904
[TBL] [Abstract][Full Text] [Related]
20. Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study.
Polivkova S; Krutova M; Capek V; Sykorova B; Benes J
Int J Infect Dis; 2021 Feb; 103():226-233. PubMed ID: 33188906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
